DeepHealth Completes Acquisition of iCAD, Expanding AI-Powered Breast Cancer Solutions Worldwide
RadNet, Inc. has completed its acquisition of iCAD, Inc. through DeepHealth, enhancing AI-powered breast cancer solutions. This integration aims to accelerate AI adoption and improve access to advanced screening technologies globally. With iCAD’s AI portfolio and presence in over 1,500 healthcare locations, the partnership targets scaling DeepHealth’s impact to over 10 million mammograms annually, enhancing cancer detection and workflow efficiency.
RadNet, Inc. has announced the completion of its acquisition of iCAD, Inc. through its wholly-owned subsidiary, DeepHealth. This strategic move integrates iCAD’s commercial, technology, and regulatory capabilities into DeepHealth, enhancing its AI-powered breast cancer image interpretation and workflow solutions. The acquisition is expected to accelerate AI adoption and expand access to advanced breast cancer screening and diagnostic technologies globally. With iCAD’s extensive AI portfolio and an installed base in over 1,500 healthcare locations worldwide, the partnership aims to scale DeepHealth’s impact to over 10 million mammograms annually, improving cancer detection rates and workflow efficiency. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iCAD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001039), on July 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
